Power Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 25-07-2024
- Paid Up Capital ₹ 4.00 M
as on 25-07-2024
- Company Age 27 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.17 Cr
as on 25-07-2024
- Revenue 13.20%
(FY 2023)
- Profit -20.62%
(FY 2023)
- Ebitda -8.80%
(FY 2023)
- Net Worth 6.10%
(FY 2023)
- Total Assets -6.59%
(FY 2023)
About Power Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹7.17 Cr.
Anil Shanta, Anilkumar Jain, and Nandu Bala serve as directors at the Company.
- CIN/LLPIN
U51909TN1997PTC039283
- Company No.
039283
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Oct 1997
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Power Pharmaceuticals Private Limited offer?
Power Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Fitness Supplements, Digestive System Drugs & Medicines, Pre & Probiotic Capsule.
Who are the key members and board of directors at Power Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Shanta  | Director | 24-Mar-2015 | Current |
| Anilkumar Jain | Whole-Time Director | 22-Oct-1997 | Current |
| Nandu Bala | Director | 24-Dec-1999 | Current |
Financial Performance of Power Pharmaceuticals.
Power Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.2% increase. The company also saw a substantial fall in profitability, with a 20.62% decrease in profit. The company's net worth moved up by a moderate rise of 6.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Power Pharmaceuticals?
In 2023, Power Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 May 2020 | ₹0.79 M | Open |
Others Creation Date: 30 May 2020 | ₹4.00 Cr | Open |
United Bank Of India Creation Date: 25 Nov 2019 | ₹0.90 M | Open |
How Many Employees Work at Power Pharmaceuticals?
Power Pharmaceuticals has a workforce of 73 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Power Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Power Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
